Essential Hypertension
Conditions
Brief summary
This study was an randomized, double-Blind, placebo-controlled, multicenter Phase II/III study.
Detailed description
The trial was divided into three parts: a screening period, a treatment period, and an open-label safety observation period, in which the screening period consisted of screening and placebo elution, and the treatment period consisted of the test drug administration period and a randomized placebo withdrawal period.the entire trial process lasts at least 3 months (excluding the screening period).
Interventions
DRUGValsartan Oral Solution
Valsartan oral solution, taken by mouth, once daily. It is recommended that the medication be administered at the same time each day (e.g., in the morning). The dose administered is based on the subject's weight at the V1 visit: Halve dose: \<35 kg: 7 mL (equivalent to valsartan 20 mg); * 35 kg: 13 mL (equivalent to valsartan 40 mg). Full dose: \<35 kg: 13 mL (equivalent to valsartan 40 mg); * 35 kg: 27 mL (equivalent to valsartan 80 mg).
DRUGPlacebo
placebo, taken by mouth, once daily. It is recommended that the medication be administered at the same time each day (e.g., in the morning). The dose administered is based on the subject's weight at the V1 visit: Full dose: \<35 kg: 13 mL ; * 35 kg: 27 mL . Placebo dosing during elution phase: \<35 kg: 7 mL; * 35 kg: 13 mL.
Sponsors
Shandong New Time Pharmaceutical Co., LTD
Study design
Allocation
NA
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
6 Years to 17 Years
Healthy volunteers
No
Inclusion criteria
1. 6 years old ≤ age ≤ 17 years old, male or female; 2. 18kg ≤ weight ≤ 160kg; 3. Initial diagnosis of essential hypertension or previous history of essential hypertension at the V1 visit, mean seated systolic blood pressure (MSSBP) and/or mean seated diastolic blood pressure (MSDBP) before the first administration of medication (at the V2 visit) at least in the 95th percentile for the same age, sex, and height (with reference to the Chinese Guidelines for the Prevention and Control of Hypertension, Revised Edition 2018 for Chinese children aged 3-17 years for each year of age, height corresponding blood pressure standard) and meets the criteria for hypertension medication; 4. Vital organ function meets the following requirements: Blood routine: hemoglobin ≥ 90 g/L, platelet count ≥ 100 × 109 /L, serum potassium ≤ 5.3 mmol/L; Liver function: ALT and AST ≤ 3 × ULN, total bilirubin level (TBIL) ≤ 2 × ULN; Renal function: glomerular filtration rate ≥ 30 mL/min/1.73 m2 (see Appendix 1 for calculation formula); 5. The legal guardian and/or the person himself/herself voluntarily signed the informed consent form.
Exclusion criteria
1. those with confirmed or previous hypertensive emergencies, hypertensive sub-emergencies; 2. Patients with secondary hypertension; 3. Medication adherence \<80% and/or \>120% during the placebo washout period at the V2 visit; 4. Patients with diabetes mellitus judged uncontrollable by the investigator; 5. Persons with associated electrolyte disturbances (e.g., severe hyponatremia); 6. those with a prior history of biliary cirrhosis and cholestasis; 7. persons with a prior history of organ transplantation; 8. patients with known active gastritis, duodenal ulcer or gastric ulcer or gastrointestinal/rectal bleeding within 3 months prior to the first dose; 9. Patients with a history of clinically significant drug/food allergy (within 6 months prior to first dose) or history of atopic allergic disease (e.g., asthma, etc.) or known allergy to valsartan and its excipients or other angiotensin II receptor antagonists (ARBs) and/or angiotensin converting enzyme inhibitors (ACEIs); 10. Persons who are infectious disease screen positive for hepatitis B surface antigen and/or core antibody and test positive for HBV-DNA, hepatitis C virus antibody positive and test positive for RNA, HIV positive, or syphilis spirochete antibody positive; 11. Persons who have been treated with any other clinical trial drug/device within 1 month prior to the first dose or within 5 half-lives of the trial drug, whichever is shorter; 12. Females with a history of menstruation who have had a positive pregnancy test; 13. Those who may not be able to complete the study for other reasons or those who, in the opinion of the investigator, are not suitable for inclusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in mean seated systolic blood pressure (MSSBP) from the end of week 6 to the end of week 8 in the valsartan oral solution group compared to the placebo group. | 2 weeks of randomized placebo withdrawal period |
Secondary
| Measure | Time frame |
|---|---|
| Change in MSSBP and MSDBP from baseline to the end of week 6 | 6 weeks of Trial drug administration period |
| Change in MSSBP and MSDBP from baseline to the end of week 8 | 8 weeks of Trial drug administration period and randomized placebo withdrawal period |
| Change in mean seated diastolic blood pressure (MSDBP) from the end of week 6 to the end of week 8 | 2 weeks of randomized placebo withdrawal |
| Adverse events (AEs)/serious adverse events (SAEs) were collected by vital signs, physical examination, laboratory tests, and 12-lead electrocardiogram to assess safety | up to 3 months |
| Palatability evaluation by VAS (visual analog scale) | the first 8 days of treatment |
| Blood pressure control rate | 8 weeks of Trial drug administration period and randomized placebo withdrawal period |
Countries
China
Outcome results
None listed